Immunic Reports $32.6 Million Net Loss and $186.6 Million Cash Reserves in Latest 10-Q Filing

Immunic, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company recorded a net loss of $32.6 million, an increase of 28% from the $25.5 million loss reported in the same period last year. Total operating expenses rose to $33.2 million, up 24% from $26.8 million in the prior year, primarily driven by a 19% increase in research and development expenses, which reached $25.6 million. General and administrative expenses also saw a notable increase of 44%, totaling $7.6 million, largely due to higher personnel costs and stock-based compensation.

In terms of liquidity, Immunic reported cash and cash equivalents of approximately $186.6 million as of March 31, 2026, a substantial increase from $15.5 million at the end of 2025. This increase was primarily attributed to a successful private placement in February 2026, which generated net proceeds of $187.3 million. The company has raised a total of approximately $684.9 million since its inception in 2016, but it has yet to generate any revenue from product sales, maintaining an accumulated deficit of $641.2 million.

Strategically, Immunic has been active in its clinical development programs, particularly with its lead candidate, vidofludimus calcium (IMU-838), which is currently in Phase 3 trials for relapsing multiple sclerosis (RMS). The company has also initiated a reverse stock split at a ratio of 1-for-10, effective April 27, 2026, to enhance its stock price and comply with Nasdaq listing requirements. Additionally, Immunic is exploring strategic alternatives for its IMU-856 program, which targets gastrointestinal diseases, and has made organizational changes, including the appointment of Michael A. Panzara as Chief Medical Officer.

Operationally, Immunic reported a headcount of approximately 95 employees as of April 30, 2026. The company continues to focus on advancing its clinical trials and expanding its research capabilities, particularly in Germany and Australia. The ongoing development of its product candidates is expected to incur significant expenses, and the company anticipates fluctuating operating losses in the future as it navigates the complexities of clinical trials and regulatory approvals. Looking ahead, Immunic aims to leverage its financial resources to support its development pipeline and explore potential partnerships to enhance its market position.